Pharmacogenetics in older people: What we know and what we need to know

Journal of Nephrology

Volumn 25, Issue SUPPL.19, 2012, Pages

  Seripa, Davide ^a   Paroni, Giulia ^a   Urbano, Maria ^a   Santini, Stefano A ^a   D'Onofrio, Grazia ^a   Pilotto, Alberto ^a,b  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b S ANTONIO HOSPITAL   (Italy)

Author keywords

Adverse drug reaction; Drug metabolizing enzyme; Drug transporter; Elderly; Pharmacogenetics; Therapeutic failure

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; CHOLINESTERASE INHIBITOR; CLOPIDOGREL; CYTOCHROME P450; DONEPEZIL; DRUG METABOLIZING ENZYME; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MULTIDRUG RESISTANCE PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROTON PUMP INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TICLOPIDINE; WARFARIN;

ALZHEIMER DISEASE; ARTICLE; CAUSE OF DEATH; CLINICAL PRACTICE; DEPRESSION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; ELDERLY CARE; GASTROINTESTINAL HEMORRHAGE; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GERIATRICS; HUMAN; LENGTH OF STAY; PHARMACODYNAMICS; PHARMACOGENETICS; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; BIOLOGICAL TRANSPORT; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; TREATMENT FAILURE;

EID: 84872047801     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000137     Document Type: Article

References (70)

1. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med. 2005;352(21): 2211-2221.
2. Ingelman-Sundberg M, Rodriguez-Antona C. Pharmacoge-netics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy. Philos Trans R Soc Lond B Biol Sci. 2005;360(1460):1563-1570.
3. Franceschi M, Scarcelli C, Niro V, et al. Prevalence, clinical features and avoidability of adverse drug reactions as cause of admission to a geriatric unit: a prospective study of 1756 patients. Drug Saf. 2008;31(6):545-556.
4. Roden DM, Altman RB, Benowitz NL, et al. Pharmacogenet-ics Research Network. Pharmacogenomics: challenges and opportunities. Ann Intern Med. 2006;145(10):749-757.
5. Nebert DW, Zhang G, Vesell ES. From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions. Drug Metab Rev. 2008;40(2): 187-224.
6. Seripa D, Pilotto A, Panza F, Matera MG, Pilotto A. Pharma-cogenetics of cytochrome P450 (CYP) in the elderly. Ageing Res Rev. 2010;9(4):457-474.
7. Gardiner SJ, Begg EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev. 2006;58(3): 521-590.
8. The Human Cytochrome P450 (CYP) Allele Nomenclature Database. Availabe at: http://www.cypalleles.ki.se/. Accessed November 10, 2011.
9. Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci. 1999; 20(8):342-349.
10. Caraco Y. Genes and the response to drugs. N Engl J Med. 2004;351(27):2867-2869.
11. International Transporter Consortium, Giacomini KM, Huang SM, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9(3):215-236.
12. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-gly-coprotein expression and activity in vivo. Proc Natl Acad Sci USA. 2000;97(7):3473-3478.
13. Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009;158(3):693-705.
14. Lewis HD Jr, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1983;309(7): 396-403.
15. Agúndez JA, Martínez C, Pérez-Sala D, Carballo M, Torres MJ, García-Martín E. Pharmacogenomics in aspirin intolerance. Curr Drug Metab. 2009;10(9):998-1008.
16. Shiotani A, Sakakibara T, Yamanaka Y, et al. The preventive factors for aspirin-induced peptic ulcer: aspirin ulcer and corpus atrophy. J Gastroenterol. 2009;44(7):717-725.
17. Pilotto A, Seripa D, Franceschi M, et al. Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduode-nal bleeding: role of cytochrome P450 2C9 polymorphisms. Gastroenterology. 2007;133(2):465-471.
18. Knights KM, Drogemuller CJ. Xenobiotic-CoA ligases: kinetic and molecular characterization. Curr Drug Metab. 2000;1(1):49-66.
19. Ha-Duong NT, Dijols S, Macherey AC, Goldstein JA, Dan-sette PM, Mansuy D. Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19. Biochemistry. 2001;40(40):12112-12122.
20. Shuldiner AR, O'Connell JR, Bliden K P, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302(8):849-857.
21. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363-375.
22. Collet J P, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009; 373(9660):309-317.
23. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(4):354-362.
24. Mega JL, Simon T, Collet J P, et al. Reduced-function CY-P2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010;304(16):1821-1830.
25. Fuster V, Sweeny JM. Clopidogrel and the reduced-function CYP2C19 genetic variant: a limited piece of the overall therapeutic puzzle. JAMA. 2010;304(16):1839-1840.
26. US Food and Drug Administration. Plavix (clopidogrel bisul-fate) 75 mg tablets. May, 2009. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm165166.htm. Accessed November 12, 2011.
27. Bai J P. Ongoing challenges in drug interaction safety: from exposure to pharmacogenomics. Drug Metab Pharmacoki-net. 2010;25(1):62-71.
28. Wallentin L, James S, Storey R F, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010;376(9749):1320-1328.
29. Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. 2010;376(9749): 1312-1319.
30. Giusti B, Abbate R. Response to antiplatelet treatment: from genes to outcome. Lancet. 2010;376(9749):1278-1281.
31. US Food and Drug Administration. FDA Approves Updated Warfarin (Coumadin) Prescribing Information. New Genetic Information May Help Providers Improve Initial Dosing Estimates of the Anticoagulant for Individual Patients. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnounce-ments/2007/ucm108967.htm. Accessed November 12, 2011.
32. Breckenridge A, Orme M, Wesseling H. Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin Pharmacol Ther. 1974;15(4):424-430.
33. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: A comprehensive review of the in-vitro and human data. Pharmacogenetics. 2002;12(3):251-263.
34. Rane A, Lindh JD. Pharmacogenetics of anticoagulants. Hum Genomics Proteomics. 2010; 754919.
35. Rieder MJ, Reiner A P, Gage B F, et al. Effect of VKORC1 hap-lotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005;352(22):2285-2293.
36. Takeuchi F, McGinnis R, Bourgeois S, et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 2009;5(3):e1000433.
37. Wadelius M, Chen LY, Lindh JD, et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood. 2009;113(4):784-792.
38. International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360(8):753-764.
39. Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenet-ics of coumarinic oral anticoagulants. Pharmacogenomics. 2010;11(4):493-496.
40. Pilotto A, Franceschi M, Vitale D F, et al. Upper gastrointestinal symptoms and therapies in elderly out-patients, users of non-selective NSAIDs or coxibs. Aliment Pharmacol Ther. 2005;22(2):147-155.
41. Drug bank. Available at: http://www.drugbank.ca/. Accessed March 15, 2012
42. Kircheiner J, Brockmoller J. Clinical consequences of cy-tochrome P450 2C9 polymorphisms. Clin Pharmacol Ther. 2005;77(1):1-15.
43. Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton VP Jr, Ridker PM. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA. 2004;291(23):2821-2827.
44. Medina MW, Gao F, Ruan W, Rotter JI, Krauss RM. Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin. Circulation. 2008;118(4):355-362.
45. Klotz U. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int J Clin Pharmacol Ther. 2006;44(7):297-302.
46. Lou HY, Chang CC, Sheu MT, Chen YC, Ho HO. Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism. Eur J Clin Pharmacol. 2009;65(1):55-64.
47. Cummings JL. Alzheimer's disease. N Engl J Med. 2004; 351(1):56-67.
48. Varsaldi F, Miglio G, Scordo MG, et al. Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients. Eur J Clin Pharmacol. 2006;62(9): 721-726.
49. Zanger UM, Fischer J, Raimundo S, et al. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics. 2001;11(7):573-585.
50. Gaedigk A, Ryder DL, Bradford LD, Leeder JS. CYP2D6 poor metabolizer status can be ruled out by a single genotyping assay for the -1584G promoter polymorphism. Clin Chem. 2003;49(6Pt1):1008-1011.
51. Pilotto A, Franceschi M, D'Onofrio G, et al. Effect of a CY-P2D6 polymorphism on the efficacy of donepezil in Alzheimer's disease patients. Neurology. 2009;73(10):761-767.
52. Seripa D, Bizzarro A, Pilotto A, et al. Role of cytochrome P4502D6 functional polymorphisms in the efficacy of done-pezil in patients with Alzheimer's disease. Pharmacogenet Genomics. 2011;21(4)225-230.
53. Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002;34 (1-2):83-448.
54. Cacabelos R. Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics. Neuropsychiatr Dis Treat. 2007;3(3):303-333.
55. Unützer J. Clinical practice. Late-life depression. N Engl J Med. 2007;357(22):2269-2275.
56. Gottfries CG. Late life depression. Eur Arch Psychiatry Clin Neurosci. 2001;251(Suppl2):57-61.
57. NIH Consensus Conference. Diagnosis and treatment of depression in late life. JAMA. 1992;268(8):1018-1024.
58. Stahl SM. Mechanism of action of serotonin selective reup-take inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord. 1998; 51(3):215-235.
59. Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003;301(5631):386-389.
60. Cervilla JA, Rivera M, Molina E, et al. The 5-HTTLPR s/s genotype at the serotonin transporter gene (SLC6A4) increases the risk for depression in a large cohort of primary care attendees: the PREDICT-Gene Study. Am J Med Genet B Neuropsychiatr Genet. 2006;141B(8):912-917.
61. Heils A, Teufel A, Petri S, et al. Allelic variation of human serotonin transporter gene expression. J Neurochem. 1996:66(6): 2621-2624.
62. Gelernter J, Freimer M. PstI RFLP at the SERT locus. Hum Mol Genet. 1994;3(2):383.
63. Gerretsen P, Pollock BG. Pharmacogenetics and the serotonin transporter in late-life depression. Expert Opin Drug Metab Toxicol. 2008;4(12):1465-1478.
64. Keers R, Uher R, Huezo-Diaz P, et al. Interaction between serotonin transporter gene variants and life events predicts response to antidepressants in the GENDEP project. Phar-macogenomics J. 2011;11(2):138-145.
65. Lacasse JR, Leo J. Serotonin and depression: a disconnect between the advertisements and the scientific literature. PLoS Med. 2005;2(12):e392.
66. König J, Seithel A, Gradhand U, Fromm M F. Pharmacoge-nomics of human OATP transporters. Naunyn Schmiede-bergs Arch Pharmacol. 2006;372(6):432-443.
67. Seithel A, Glaeser H, Fromm M F, König J. The functional consequences of genetic variations in transporter genes encoding human organic anion-transporting polypeptide family members. Expert Opin Drug Metab Toxicol. 2008;4(1):51-64.
68. Brandsch M, Knütter I, Bosse-Doenecke E. Pharmaceutical and pharmacological importance of peptide transporters. J Pharm Pharmacol. 2008;60(5):485-543.
69. Al-Ghoul M, Valdes R Jr. Fundamentals of pharmacology and applications in pharmacogenetics. Clin Lab Med. 2008;28(4):485-497.
70. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Available at: http://medicine.iupui.edu/clinpharm/ddis/. Accessed March 3, 2012